Pasireotide Diaspartate

CAS No:
820232-50-6 Categories: , ,
  • #LGM Pharma is a Pasireotide Diaspartate CAS# 820232-50-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 820232-50-6
  • AHFC code:
  • Synonyms: Cyclo((2R)-2-phenylglycyl-d-tryptophyl-l-lysyl-o-(phenylmethyl)-l-tyrosyl-l-phenylalanyl-(4R)-4-((((2-aminoethyl)amino)carbonyl)oxy)-l-prolyl), l-aspartate (1:2), Pasireotide diaspartate, Pasireotide diaspartate [EMA EPAR], Signifor, UNII-I4P76SY3N4
  • ATC Code: H01CB05
  • Chemical Formula: C58-H66-N10-O9.2C4-H7-N-O4
  • Molecular Weight: 1313.425
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB06663
  • SMILES: c1ccc(cc1)C[C,H]2C(=O)N3C[C,,H](C[C,H]3C(=O)N[C,H](C(=O)N[C,,H](C(=O)N[C,H](C(=O)N[C,H](C(=O)N2)Cc4ccc(cc4)OCc5ccccc5)CCCCN)Cc6c[nH]c7c6cccc7)c8ccccc8)OC(=O)NCCN.C([C,,H](C(=O)O)N)C(=O)O.C([C,,H](C(=O)O)N)C(=O)O
  • InChl:
  • PubChem:
  • IUPAC:

Additional Details

Indication:
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
Pharmacodynamics:
Signifor® is an analogue of somatostatin that promotes reduced levels of cortisol secretion in Cushing's disease patients.
Mode of Action:
Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing's disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.
Metabolism:
Metabolism is minimal.
Toxicity:
The most common toxic effects observed are hyperglycemia, cholelithiasis, diarrhea, nausea, headache, abdominal pain, fatigue, and diabetes mellitus.
General Reference:
Weckbecker G, Briner U, Lewis I, Bruns C: SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002 Oct;143(10):4123-30. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials